DK0922034T3 - Tetrahydroquinolinderivater som EAA-antagonister - Google Patents

Tetrahydroquinolinderivater som EAA-antagonister

Info

Publication number
DK0922034T3
DK0922034T3 DK97943809T DK97943809T DK0922034T3 DK 0922034 T3 DK0922034 T3 DK 0922034T3 DK 97943809 T DK97943809 T DK 97943809T DK 97943809 T DK97943809 T DK 97943809T DK 0922034 T3 DK0922034 T3 DK 0922034T3
Authority
DK
Denmark
Prior art keywords
tetrahydroquinoline derivatives
eaa antagonists
eaa
antagonists
tetrahydroquinoline
Prior art date
Application number
DK97943809T
Other languages
Danish (da)
English (en)
Inventor
Fabio Maria Sabbatini
Romano Di-Fabio
Alessandra Pasquarello
Original Assignee
Glaxosmithkline Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Spa filed Critical Glaxosmithkline Spa
Application granted granted Critical
Publication of DK0922034T3 publication Critical patent/DK0922034T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK97943809T 1996-08-17 1997-08-14 Tetrahydroquinolinderivater som EAA-antagonister DK0922034T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9617305.9A GB9617305D0 (en) 1996-08-17 1996-08-17 Heterocyclic compounds
PCT/EP1997/004440 WO1998007704A1 (en) 1996-08-17 1997-08-14 Tetrahydroquinoline derivatives as eaa antagonists

Publications (1)

Publication Number Publication Date
DK0922034T3 true DK0922034T3 (da) 2002-11-18

Family

ID=10798623

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97943809T DK0922034T3 (da) 1996-08-17 1997-08-14 Tetrahydroquinolinderivater som EAA-antagonister

Country Status (34)

Country Link
US (1) US6479488B1 (de)
EP (1) EP0922034B1 (de)
JP (1) JP4108129B2 (de)
KR (1) KR100552864B1 (de)
CN (1) CN1131214C (de)
AP (1) AP877A (de)
AR (1) AR008296A1 (de)
AT (1) ATE221052T1 (de)
AU (1) AU724473B2 (de)
BR (1) BR9711311B1 (de)
CA (1) CA2264118C (de)
CO (1) CO4900066A1 (de)
CZ (1) CZ296250B6 (de)
DE (1) DE69714265T2 (de)
DK (1) DK0922034T3 (de)
EA (1) EA001704B1 (de)
ES (1) ES2181030T3 (de)
GB (1) GB9617305D0 (de)
HU (1) HU225797B1 (de)
ID (1) ID18095A (de)
IL (1) IL128141A0 (de)
IS (1) IS4953A (de)
MY (1) MY116952A (de)
NO (1) NO312241B1 (de)
NZ (1) NZ333812A (de)
PE (1) PE107098A1 (de)
PL (1) PL194532B1 (de)
PT (1) PT922034E (de)
SI (1) SI0922034T1 (de)
TR (1) TR199900336T2 (de)
TW (1) TW449582B (de)
WO (1) WO1998007704A1 (de)
YU (1) YU6799A (de)
ZA (1) ZA977326B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706294D0 (en) * 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
BR0215430A (pt) * 2001-12-28 2004-12-14 Acadia Pharm Inc Composto e seus usos, composição, método de tratamento, método de aumento d atividade de um receptor colinérgico, método de tratamento e prevenção ou redução dos sintomas associados à disfunção em mamìferos
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
MXPA05007784A (es) * 2003-01-23 2005-09-30 Acadia Pharm Inc Empleo de la n-desmetilclozapina para tratar las enfermedades neuropsiquiatricas humanas.
EP1596867A4 (de) * 2003-02-19 2006-03-22 Merck & Co Inc Behandlung von psychose mit einem muscarinischen m1 rezeptor ektopischen aktivator
PL1696931T3 (pl) * 2003-12-22 2009-10-30 Acadia Pharm Inc Aminopodstawione analogi diarylo[A,D]cykloheptenowe jako agoniści receptorów muskarynowych i sposoby leczenia chorób neuropsychiatrycznych
MXPA06011320A (es) * 2004-04-01 2007-03-21 Acadia Pharm Inc Metodo de sintesis y aislamiento de n-desmetilclozapina solida y sus formas cristalinas.
CA2616079C (en) * 2005-07-22 2012-09-25 Mochida Pharmaceutical Co., Ltd. Novel heterocyclidene acetamide derivative
RU2451014C2 (ru) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
WO2007033082A2 (en) * 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (dmso)
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
JP5399072B2 (ja) 2005-09-12 2014-01-29 アベラ ファーマスーティカルズ インコーポレイテッド ジメチルスルホキシド（ｄｍｓｏ）若しくは関連化合物、又はそれに関連する臭気を除去するシステム
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
EP2493314B1 (de) 2009-10-30 2020-04-08 Abela Pharmaceuticals, Inc. Dimethylsulfoxid (dmso)- und methylsulfonylmethan (msm)-formulierungen zur behandlung von osteoarthritis
EP2763676B1 (de) 2011-10-03 2019-12-25 The University of Utah Research Foundation Verwendung von 5-ht6-rezeptorantagonisten zur linderung von kognitiven defiziten von down-syndrom

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386839B1 (de) 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinolin-Derivate, verwendbar bei neurodegenerativen Krankheiten
EA000875B1 (ru) 1995-09-29 2000-06-26 ГЛАКСО ВЕЛЛКАМ С.п.А. Тетрагидрохинолины в качестве антагонистов nmda (n-метил-d-аспарагиновой кислоты)

Also Published As

Publication number Publication date
TW449582B (en) 2001-08-11
HUP9903108A3 (en) 2004-04-28
KR20000068172A (ko) 2000-11-25
EP0922034B1 (de) 2002-07-24
BR9711311B1 (pt) 2009-01-13
ID18095A (id) 1998-02-26
TR199900336T2 (xx) 1999-04-21
CN1131214C (zh) 2003-12-17
DE69714265D1 (de) 2002-08-29
EA199900121A1 (ru) 1999-10-28
NZ333812A (en) 2000-07-28
AP877A (en) 2000-09-27
NO990723L (no) 1999-04-14
GB9617305D0 (en) 1996-09-25
US6479488B1 (en) 2002-11-12
CZ296250B6 (cs) 2006-02-15
JP2001508031A (ja) 2001-06-19
EA001704B1 (ru) 2001-06-25
MY116952A (en) 2004-04-30
PT922034E (pt) 2002-12-31
HU225797B1 (en) 2007-09-28
AP9901459A0 (en) 1999-03-31
DE69714265T2 (de) 2003-03-06
IL128141A0 (en) 1999-11-30
EP0922034A1 (de) 1999-06-16
CO4900066A1 (es) 2000-03-27
PE107098A1 (es) 1999-01-15
AU4551897A (en) 1998-03-06
BR9711311A (pt) 1999-08-17
CN1227544A (zh) 1999-09-01
WO1998007704A1 (en) 1998-02-26
NO990723D0 (no) 1999-02-16
AR008296A1 (es) 1999-12-29
IS4953A (is) 1999-01-22
SI0922034T1 (en) 2003-02-28
YU6799A (sh) 2000-03-21
KR100552864B1 (ko) 2006-02-20
ES2181030T3 (es) 2003-02-16
CA2264118C (en) 2008-06-17
JP4108129B2 (ja) 2008-06-25
CZ52999A3 (cs) 1999-07-14
PL194532B1 (pl) 2007-06-29
ATE221052T1 (de) 2002-08-15
AU724473B2 (en) 2000-09-21
ZA977326B (en) 1999-02-15
PL331562A1 (en) 1999-07-19
CA2264118A1 (en) 1998-02-26
NO312241B1 (no) 2002-04-15

Similar Documents

Publication Publication Date Title
DK0922034T3 (da) Tetrahydroquinolinderivater som EAA-antagonister
NO20013003D0 (no) Kinolin-derivater
DK1073639T3 (da) Chinolinderivater
ATE250036T1 (de) Chinolinderivate
NO965036D0 (no) Kinolinderivater som techykinin NK3 reseptor-antagonister
DE69720493T2 (de) Naphthyridin-derivate
ATE240327T1 (de) 1,2-annelierte chinolinderivate
EE9800219A (xx) Uued 19-nor-pregneeni derivaadid
ATE229005T1 (de) Chinolinderivate
NO991384D0 (no) Substituerte heterocykler som anti-tumormidler
NO974043L (no) Indolderivater som EAA-antagonister
ATE255098T1 (de) Substituierte chromanderivate
NO991560D0 (no) PDE IV som inhiberer 2-cyanoiminoimidazol-derivater
ATE255099T1 (de) Substituierte chromanderivate
DK0854867T3 (da) Tetrahydroquinoliner som NMDA-antagonister
DK1086093T3 (da) Tetrahydroquinolinderivater som glycinantagonister
PT931087E (pt) Novos derivados de piranosido
FI970143A0 (fi) Kinoliinijohdannaiset leukotrieeniantagonisteina